Study details
Enrolling now
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
Virginia Commonwealth University
NCT IDNCT05886582ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
40
Study length
about 2.8 years
Ages
25–70
Locations
1 site in VA
About this study
Researchers are testing whether rotigotine, a medication applied through the skin (Neupro), can help people with cocaine use disorder reduce their drug use and improve cognitive control when used in combination with behavioral therapy. The trial will last 1023 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Rotigotine Transdermal System [Neupro]
PhasePhase 2
DrugRotigotine Transdermal System [Neupro]
Routetransdermal
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
NERVOUS SYSTEM
Drug routes
transdermal
Body systems
Psychiatry / Mental Health